Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).
Here are six LD deals that have been publicly confirmed subsequent to their approvals.
PANTHERx Rare to Distribute Vigafyde
PANTHERx Rare was selected by Upsher-Smith for the distribution of Vigafyde (vigabatrin), a ready-to-use, concentrated oral solution approved for the treatment of infantile spasms in pediatric patients one month to two years old.
PANTHERx Rare to Distribute Vykat
PANTHERx Rare was selected by Soleno Therapeutics to distribute Vykat XR (diazoxide choline extended-release tablets), for the treatment of hyperphagia in individuals four years of age and older with Prader-Willi syndrome (PWS).
Orsini Specialty Pharmacy has been selected by Neurotech Pharmaceuticals, Inc., as the exclusive specialty pharmacy partner for Encelto (revakinagene taroretcel-lwey), an FDA-approved encapsulated cell therapy implant for the treatment of Macular Telangiectasia type 2 (MacTel).
CareMed to Distribute Vanrafia
CareMed has been selected by Novartis Pharmaceuticals to join the Limited Distribution Network for Vanrafia (atrasentan), indicated for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and are at risk of rapid disease progression.
(CareMed is an independent Specialty Pharmacy that is an affiliate of Onco360 Specialty Pharmacy)
Soleo Health to Distribute Qfitlia
Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi. Qfitlia is the first antithrombin-lowering therapy for hemophilia. Qfitlia was approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with hemophilia A or B with or without factor VIII or IX inhibitors.
Onco360 to Distribute Avmapki – Fakzynja CO-PACK
Onco360 has been selected as a national pharmacy partner by Verastem Oncology for Avmapki – Fakzynja CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
